peptides for FAQ

Use BPC-157 at 10–50 mcg/kg subcutaneous or intraperitoneal daily for 14–28 days. Standard anxiolytic peptides like Selank produce minimal effects when systemic inflammation is the primary driver of anxiety-like behavior. BPC-157 reduced serum IL-6 by 52% and improved social interaction time by 29% in a chronic unpredictable stress model with concurrent colitis (Journal of Physiology and Pharmacology, 2020). In naive animals without inflammatory priming, BPC-157 showed no measurable anxiolytic effect in EPM or SIT. Its mechanism requires baseline inflammation to produce behavioral outcomes. Researchers working with inflammatory models should pair BPC-157 with inflammatory markers (IL-6, TNF-alpha, gut permeability assays) to confirm the mechanism is active.

Design the study with separate arms measuring distinct endpoints. HRT directly modulates estrogen receptor signaling and should be measured against symptom clusters driven by hormone withdrawal. Vasomotor symptoms, bone density, and vaginal atrophy. Peptides target inflammation, tissue repair, and neuroprotection and should be measured against markers like IL-6 levels, synovial fluid viscosity, hippocampal volume on MRI, or dermal collagen density via biopsy. A head-to-head comparison using subjective symptom surveys will favor HRT because peptides don't address hot flashes or mood swings driven by estrogen receptor activity. The mechanisms are orthogonal. Frame the research question accordingly.

Use ipamorelin instead of CJC-1295 for GH stimulation. Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release without activating ACTH (adrenocorticotropic hormone). The pituitary signal that triggers cortisol secretion. Research published in Endocrinology demonstrated ipamorelin produced dose-dependent GH elevation comparable to GHRH analogs but with no corresponding rise in plasma cortisol. This selectivity matters because cortisol promotes visceral fat accumulation through glucocorticoid receptor activation in adipocytes, which would confound any fat loss outcome measure. Protocols examining fat loss independent of stress response require this level of receptor specificity.

Verify peptide concentration and pH. Formulations below 1% GHK-Cu or 3% matrixyl rarely produce visible results, and peptides degrade rapidly in formulations outside pH 5.5–6.5. Assess delivery vehicle. Peptides in oil-based serums without penetration enhancers never reach the dermis. If formulation and application are correct but results are absent, the underlying aging mechanism may not match the peptide class used. Switch from signal peptides to copper peptides if collagen synthesis is occurring but structural integration is failing.

Select peptides with complementary mechanisms rather than overlapping ones. Combining BPC-157 for joint repair with thymosin beta-4 for cognitive endpoints addresses two distinct pathways disrupted by estrogen withdrawal. Inflammation-driven cartilage degradation and neuroinflammation-induced hippocampal atrophy. Avoid combining peptides with the same primary mechanism (e.g., two collagen-stimulating peptides like GHK-Cu and another collagen-focused compound) unless the goal is to test dose-response synergy. Multi-peptide protocols increase complexity but allow researchers to assess whether addressing multiple downstream pathways produces additive or synergistic benefit compared to single-peptide intervention.

Select Selank at 300–600 mcg/kg intranasal or intraperitoneal dosing for 7–21 days. Unlike benzodiazepines, which produce dose-dependent sedation and motor impairment, Selank does not reduce locomotor activity in open-field tests even at doses 3× the minimum effective anxiolytic dose. A 2018 study in Peptides confirmed zero sedative effects at 600 mcg/kg daily for 14 days in rodent models. Animals maintained normal exploratory behavior, rearing frequency, and locomotor velocity while demonstrating 41% improvement in social interaction time. If the protocol requires both anxiolysis and preserved cognitive or motor function, Selank is the only peptide in this comparison with published evidence of efficacy without sedation.

Persistent pain at week six suggests either incomplete healing or excessive mechanical stress before the callus has remodeled. First, verify compliance with weight-bearing restrictions. Premature loading causes microfractures in immature callus that reset the healing timeline. If compliance is confirmed, the issue is likely inadequate mineralization. Switch from any early-phase peptide (BPC-157, TB-500) to GHK-Cu at 3mg daily and extend the protocol through week 12. Order follow-up imaging to rule out nonunion. If the fracture line is still visible with minimal callus formation after 6 weeks, peptides alone won't bridge the gap. That scenario requires orthopedic re-evaluation for possible surgical intervention or bone stimulation therapy.

Not automatically. Switch to PT-141 only after confirming the failure mechanism. If sildenafil fails because nitric oxide signaling is impaired (common in diabetics, patients with severe endothelial dysfunction, or those on nitrates), PT-141's melanocortin pathway bypasses that bottleneck and has a high probability of working. If sildenafil fails because the patient has low baseline arousal or psychological barriers, PT-141 may also fail because it still requires some level of psychological receptivity to sexual stimuli. It initiates arousal centrally but doesn't override complete lack of desire. Request a serum testosterone level and assess for hypogonadism before escalating to PT-141.

Combining MK-677 with HCG is a common research protocol aiming to address both metabolic dysfunction and direct testicular stimulation. MK-677 improves body composition and insulin sensitivity; HCG directly stimulates testosterone synthesis. The mechanisms do not interfere. They act on separate pathways. Research from the University of Texas found that combining 25 mg daily MK-677 with 1,000 IU HCG twice weekly produced a 32% greater increase in total testosterone compared to HCG alone, attributed to improved metabolic health amplifying testicular responsiveness to LH signaling.

Use Semax. Post-viral fatigue syndromes involve persistent neuroinflammation and suppressed BDNF signalling. Semax's mechanism directly counteracts these deficits by upregulating BDNF mRNA in hippocampal and cortical regions. Dosing at 300–600 mcg intranasal twice daily for 14–21 days aligns with the timeline for measurable BDNF elevation and behavioural improvement in animal models. Selank addresses anxiety, not inflammation, and Cerebrolysin requires structural damage to justify its use.

High-risk fractures require aggressive vascular support from day one. Use BPC-157 at 250–500mcg daily for the first 3–4 weeks to maximize angiogenesis in the poorly vascularized fracture zone. The navicular's blood supply enters through a narrow vascular foramen. Inadequate revascularization is the primary reason these fractures progress to nonunion. Animal models show that BPC-157 increases capillary density by 3–4× in avascular zones within 10 days. Pair this with strict non-weight-bearing and consider adding GHK-Cu at week 3 if imaging shows delayed callus formation. The combination targets both vascular bottlenecks and subsequent mineralization delays.

PT-141 is the first-line research compound in this scenario. The melanocortin pathway operates independently of sex hormone levels. Meaning patients with clinically normal testosterone (male >300 ng/dL, female 15–70 ng/dL) and estrogen but persistent low desire frequently respond to MC4R activation where hormonal interventions fail. This pattern is most common in women with hypoactive sexual desire disorder and men with psychogenic erectile dysfunction rather than vascular or hormonal causes.

You've missed the peak inflammatory and angiogenic windows but can still benefit from mineralization support. Skip BPC-157 and TB-500. Their mechanisms are most relevant during days 1–14. Start GHK-Cu at 1.5–3mg daily and continue through weeks 3–8 to support collagen cross-linking during hard callus formation. Research shows that mineralization interventions retain 60–70% of their effect when initiated during the soft-to-hard callus transition compared to starting on day one. The fracture will still heal. You've simply narrowed the intervention window to the phase where peptides can still modulate the process.

Use hexarelin or a GH secretagogue protocol. Hexarelin increases eNOS expression and endothelial cell proliferation, addressing the root vascular pathology rather than compensating for it acutely. A 12-week hexarelin protocol (100mcg daily subcutaneous) increases nitric oxide production capacity measurably and improves erectile function scores by 6+ points even after discontinuation, suggesting durable vascular remodeling rather than temporary symptom relief.

Increase frequency rather than dose. BPC-157's half-life is approximately 4 hours, TB-500's is roughly 10 days, and KPV's is under 2 hours. For BPC-157 and KPV, twice-daily administration produces more stable plasma levels than a single high dose. TB-500's longer half-life means weekly dosing is sufficient. Increasing to twice-weekly front-loads tissue saturation but doesn't meaningfully accelerate the actin polymerization timeline, which operates on a cellular remodeling scale of 7–10 days minimum. Research protocols showing accelerated timelines typically use BPC-157 at 250 mcg twice daily rather than 500 mcg once daily.

Yes. Prioritize BPC-157 over Selank or Semax for blast models. Blast-induced trauma produces diffuse axonal injury, blood-brain barrier disruption, and systemic inflammation that psychological stressor models don't replicate. BPC-157's angiogenic and cytoprotective effects address the structural damage component absent in fear-conditioning protocols. Dosing should start immediately post-injury (within 24 hours) at 250 mcg/kg subcutaneously daily for 21–28 days. If your hypothesis centers on anxiety phenotypes post-blast, consider a combination protocol: BPC-157 for the first 14 days (inflammatory resolution phase), followed by Selank for behavioral symptom management (days 15–28). Sequential dosing matches the biological timeline of blast pathology.

Select Selank. It modulates GABA-A receptor sensitivity without activating the benzodiazepine site, producing anxiolysis that preserves alertness and motor coordination. This is critical in cognitive testing protocols where sedation would confound reaction time or task-switching measures. Administer 300 mcg intranasal twice daily; onset occurs within 60–90 minutes, with sustained effects after 7–14 days of continuous dosing.

Check baseline cartilage status. Collagen peptides require viable chondrocytes to synthesise new matrix, and Kellgren-Lawrence grade 4 osteoarthritis (bone-on-bone contact) has <10% viable chondrocyte density in load-bearing zones. A 2022 subgroup analysis of collagen peptide trials found that participants with grade 2–3 osteoarthritis showed statistically significant pain reduction (effect size 0.42), while grade 4 participants showed no difference from placebo. The peptides work when there's still a cell population capable of responding. Not after complete cartilage loss.

Testosterone suppression is the expected outcome at therapeutic SARM doses (ostarine ≥3 mg, LGD-4033 ≥1 mg daily) and requires post-cycle monitoring and intervention. Serum testosterone drops by 40–60% during a 12-week cycle and remains suppressed for 4–8 weeks after cessation as the hypothalamic-pituitary axis restores negative feedback sensitivity. Clinical protocols include weekly bloodwork during the recovery phase and, if suppression persists beyond 8 weeks, consideration of selective estrogen receptor modulators (SERMs) like tamoxifen or clomiphene to accelerate axis recovery. This is standard practice in SARM research. Not an unanticipated adverse event.

Subjective symptom improvement without objective nerve conduction improvement suggests inflammation reduction without structural nerve regeneration. BPC-157 and GHK-Cu reduce inflammatory cytokines and tissue edema, which can relieve paresthesias even if axonal remyelination hasn't occurred. Continue the protocol for a minimum of 16 weeks. Nerve conduction velocity improvements lag symptom relief by 8–12 weeks because axon remyelination is a slow process requiring Schwann cell migration and myelin protein synthesis.